{'fraction_non_alphanumeric': 0.025385312783318223, 'fraction_numerical': 0.0, 'mean_word_length': 5.610778443113772, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Medicine's arsenal in battling 'dominant dozen,' other AIDS-associated opportunistic infections.

ABSTRACT WHAT HAD SEEMED to be an endless array of opportunistic infections (OIs) in patients with acquired immunodeficiency syndrome (AIDS) now appears to be dominated by about a dozen increasingly treatable maladies.Both more and better studies are expanding the arsenal against pathogens that thrive when immune systems are damaged by human immunodeficiency virus (HIV) infection.Early evidence suggests some new drugs, including macrolide antiobiotics, may be active against two or more of the most troubling OIs, and could hold hope for single-agent oral prophylaxis where intravenous and multiagent acute treatment now is the only option. Other treatments and preventions, though far from ideal, are emerging at a rapid pace compared with the early days of the epidemic.Prevention Is Payoff "Initially the glamorous part" of AIDS research was with antivirals, says Judith E. Feinberg, MD, vice chair of the federal AIDS Clinical Trials Group opportunistic infections committee and assistant profesor